Compare

Side by side

Pick up to three peptides to see how their mechanisms, studied uses and evidence levels differ. Rows where the entries disagree are marked with a blue edge.

Selected 1 of 3

Comparison

GHRP-2 (pralmorelin)

Growth hormone secretagogue

Evidence level

Limited evidence

Approval status

Investigational

Mechanism of action

1.Activates the ghrelin receptor (GHS-R1a) on pituitary cells.
2.Produces a larger growth-hormone pulse than GHRP-6 at equivalent doses in comparative studies.
3.Stimulates appetite less than GHRP-6, which is part of its appeal in research settings.
4.Synergises with GHRH analogues, so the two are commonly studied together.
5.Increases IGF-1 secondarily with repeated use.

Studied for

Growth-hormone deficiency testing (used diagnostically in some countries)
Growth-hormone secretion research
Body-composition and recovery claims without trials
Combination with GHRH analogues

Reported effects

A pronounced growth-hormone pulse after dosing
Raised IGF-1 with repeated use
Less hunger stimulation than GHRP-6
Fluid retention and joint stiffness in the growth-hormone class

Side effects

Headache, flushing, dizziness
Water retention and joint aches
Numbness or tingling in the hands
Increased appetite
Prolactin and cortisol can rise transiently

Research protocol

Research context only — no approved protocol exists. Doses in human studies were in the microgram-per-kilogram range, given intravenously or subcutaneously for growth-hormone testing. Schedules circulated online, usually 100–300 micrograms once or twice daily, are community practice with no trial evidence behind them.

Research context only

Evidence justification

Its ability to raise growth hormone is documented in small human studies, some using it as a diagnostic agent, but the body-composition and recovery claims have not been tested in controlled trials.